A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)
Recruiting now
Conditions studied: Inflamatory Bowel Disease
In brief
Patients with refractory inflammatory bowel disease (IBD) show inadequate response to conventional biologics and small molecule drugs, with persistently active disease that severely impacts quality of life and long-term prognosis. Current treatment options are limited, and the substantial disease heterogeneity makes traditional randomized controlled trials difficult to implement in this population. This study aims to explore the efficacy and safety of guselkumab (GUS) with JAK inhibitors (such as upadacitinib/tofacitinib) in this patient population, providing novel therapeutic strategies for clinical practice.
Key facts
- Study ID
- NCT07487311
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- People needed
- 80
- Starts
- 2026-01-07
- Expected to finish
- 2028-12-31
- Last updated by the study team
- 2026-03-23
Who can join
Age: 14 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 14-80 years with confirmed diagnosis of IBD;
- Meeting the definition of refractory IBD (1. Failure of at least two biologics with different mechanisms of action; 2. Crohn's disease with recurrence after two or more intestinal resections; 3. Complex perianal disease despite treatments 1 and 2);
- Moderate to severe active IBD (CD: CDAI 220-450, SES-CD ≥6 or isolated ileal disease ≥4; UC: Baseline modified Mayo score (mMayo) of 4-9, rectal bleeding score ≥1, endoscopic score ≥2);
- Signed informed consent.
You may not qualify if…
- Active infection, abscess, malignancy, severe cardiopulmonary disease, pregnancy or lactation;
- History of thromboembolism, severe hepatic or renal insufficiency, severe cytopenia;
- Prior intolerance to JAK inhibitors or IL-23 inhibitors.
Where it is running
- Center of Inflammatory Bowel Disease, Department of Gastroenterology, the Second Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.